Pharmacoeconomics

• 

  Publication Venue For

  • Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care..  34:273-284. 2016
  • Cost-Effectiveness Analysis of Qsymia for Weight Loss..  33:699-706. 2015
  • Challenges in merging Medicaid and Medicare databases to obtain healthcare costs for dual-eligible beneficiaries: using diabetes as an example..  27:167-177. 2009
  • Economic burden of heart failure in the elderly..  26:447-462. 2008
  • Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia..  26:435-446. 2008
  • Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective..  25:343-351. 2007
  • Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial..  24:479-494. 2006
  • Impact of Medicaid preferred drug lists on therapeutic adherence..  24 Suppl 3:65-78. 2006
  • Price differentiation and transparency in the global pharmaceutical marketplace..  23:651-658. 2005
  • The impact of anaemia and its treatment on employee disability and medical costs..  23:183-192. 2005
  • The economic burden of allergic rhinitis: a critical evaluation of the literature..  22:345-361. 2004
  • Cost effectiveness of abciximab during routine medical practice..  18:265-274. 2000
  • Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndrome..  17:263-272. 2000
  • The distribution of sales revenues from pharmaceutical innovation..  18 Suppl 1:21-32. 2000
  • Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia..  16:459-472. 1999
  • Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications..  15:257-268. 1999
  • Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II..  15:141-155. 1999
  • Treating myocardial infarction in the post-GUSTO era. A US perspective..  9:473-477. 1996
  • Cost of treatment and prevention of Haemophilus influenzae type b disease. An international perspective..  6:442-452. 1994
  • The effect of Medicaid formularies on the availability of new drugs..  1:32-40. 1992